Granted Patent
B2
US 12,357,681 · App. 17/554,424 · Granted Jul 15, 2025
Patent
Inventors:
Ye Che (Niantic, CT); Laurent Oliver Chorro (New York, NY); Robert George Konrad Donald (South Orange, NJ); Matthew Curtis Griffor (North Stonington, CT); Natalie Clare Silmon de Monerri (New York, NY)
Assignee:
Pfizer Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This disclosure relates to the design of E. coli mutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.
Claims (65)
1. A mutated FimH polypeptide, which comprises: at least one amino acid substitution relative to the amino acid sequence of the wild-type FimH polypeptide, wherein the substitution is selected from the group consisting of: F1I; F1V; F1M; F1Y; F1W; P12C; G14C; G15A; GI5P; G16A; G16P; A18C; P26C; V28C; Q32C; N33C; L34N; L34S; L34T; L34D; L34E; L34K; L34R; V35C; S62C; Y64C; G65A; L68C; F71C; T86C; L107C; Y108C; L109C; V112C; S113C; A115V; G116C; V118C; A119C; A119N; A119S; A119D; A119E; A119K; A119R; A127C; L129C; F144C; V154C; V155C; V156C; T158C; and V185I, and wherein the amino acid positions are numbered according to SEQ ID NO: 59.
2. A mutated FimH polypeptide, which comprises amino acid substitutions relative to the amino acid sequence of the wild-type FimH polypeptide, wherein the amino acid substitutions selected from the group consisting of:
a) G15A and G16A;
b) P12C and A18C;
c) G14C and F144C;
d) P26C and V35C;
e) P26C and V154C;
f) P26C and V156C;
g) V27A and Q133K;
h) V28C and N33C;
i) V28C and P157C;
j) Q32C and Y108C;
k) N33C and L109C;
I) N33C and P157C;
m) V35C and L107C;
n) V35C and L109C;
o) S62C and T86C;
p) S62C and L129C;
q) Y64C and L68C;
r) Y64C and A127C;
s) L68C and F71C;
t) V112C and T158C;
u) S113C and G116C;
v) S113C and T158C;
w) V118C and V156C;
x) A119C and V155C;
y) L34N and V27A;
z) L34S and V27A;
aa) L34T and V27A;
ab) L34D and V27A;
ac) L34E and V27A;
ad) L34K and V27A;
ae) L34R and V27A;
af) A119N and V27A;
ag) A119S and V27A;
ah) A119T and V27A;
ai) A119D and V27A;
aj) A119E and V27A;
ak) A119K and V27A;
al) AI119R and V27A;
am) G15A and V27A;
an) G16A and V27A;
ao) G15P and V27A;
ap) GI6P and V27A;
aq) G15A, G16A, and V27A;
ar) G65A and V27A; and
as) G15A, G16A, V27A, and Q133K, and wherein the amino acid positions are numbered according to SEQ ID NO: 59.
3. A mutated FimH polypeptide comprising a sequence selected from the group consisting of SEQ ID NOs: 2, 3, 5-8, 10-14, 16-21, 23-46, 48-58, and 61-64.
4. The mutated FimH polypeptide according to claim 1 , wherein the polypeptide is isolated.
5. A pharmaceutical composition comprising (i) the mutated FimH polypeptide according to claim 1 and (ii) a pharmaceutically acceptable carrier.
6. An immunogenic composition comprising the mutated FimH polypeptide according to claim 1 .
7. The immunogenic composition according to claim 6 , further comprising an E. coil saccharide antigen, wherein the saccharide antigen comprises a structure selected from the group consisting of formula O25b, Formula O1A, Formula O2, and formula O6.
8. The immunogenic composition according to claim 6 , further comprising at least one adjuvant.
9. The polypeptide of claim 1 , further comprising the amino acid substitution V27A.
10. The polypeptide of claim 2 , comprising the amino acid substitutions G15A, G16A, and V27A.
11. The polypeptide of claim 1 , wherein the polypeptide is stabilized by a donor-strand peptide of FimG (FimH-DsG).
12. The mutated polypeptide of claim 3 , comprising the sequence of SEQ ID NO: 62.
13. A pharmaceutical composition comprising (i) the mutated FimH polypeptide according to claim 2 and (ii) a pharmaceutically acceptable carrier.
14. An immunogenic composition comprising the mutated FimH polypeptide according to claim 2 .
15. The immunogenic composition according to claim 14 , further comprising an E. coli saccharide antigen, wherein the saccharide antigen comprises a structure selected from the group consisting of Formula O25b, Formula O1A, Formula O2, and Formula O6.
16. The immunogenic composition according to claim 14 , further comprising at least one adjuvant.
17. A pharmaceutical composition comprising (i) the mutated FimH polypeptide according to claim 3 and (ii) a pharmaceutically acceptable carrier.
18. An immunogenic composition comprising the mutated FimH polypeptide according to claim 3 .
19. The immunogenic composition according to claim 18 , further comprising an E. coli saccharide antigen, wherein the saccharide antigen comprises a structure selected from the group consisting of Formula O25b, Formula O1A, Formula O2, and Formula O6.
20. The immunogenic composition according to claim 18 , further comprising at least one adjuvant.
Assignments (1)
ASSIGNEE ADDRESS CORRECTION
Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →
Continuity (4)
Provisional Application
63282244
· Nov 23, 2021
Provisional Application
63185425
· May 7, 2021
Provisional Application
63130153
· Dec 23, 2020
References Cited (310)
US 4709017A
· Collier et al.
· 1987
[cited by applicant]
US 4950740A
· Greenfield et al.
· 1990
[cited by applicant]
US 5340740A
· Petitte et al.
· 1994
[cited by applicant]
US 5370872A
· Cryz et al.
· 1994
[cited by applicant]
US 5614382A
· Metcalf
· 1997
[cited by applicant]
US 5656479A
· Petitte et al.
· 1997
[cited by applicant]
US 5830510A
· Petitte et al.
· 1998
[cited by applicant]
US 5843711A
· Collier et al.
· 1998
[cited by applicant]
US 5917017A
· Collier et al.
· 1999
[cited by applicant]
US 6114168A
· Samarut et al.
· 2000
[cited by applicant]
US 6194388B1
· Krieg et al.
· 2001
[cited by applicant]
US 6207646B1
· Krieg et al.
· 2001
[cited by applicant]
US 6214806B1
· Krieg et al.
· 2001
[cited by applicant]
US 6218371B1
· Krieg et al.
· 2001
[cited by applicant]
US 6239116B1
· Krieg et al.
· 2001
[cited by applicant]
US 6339068B1
· Krieg et al.
· 2002
[cited by applicant]
US 6455673B1
· Collier
· 2002
[cited by applicant]
US 6500668B2
· Samarut et al.
· 2002
[cited by applicant]
US 6749831B1
· Bennett-Guerrero et al.
· 2004
[cited by applicant]
US 7247307B2
· Szu et al.
· 2007
[cited by applicant]
US 8871214B2
· Serino et al.
· 2014
[cited by applicant]
US 9060965B2
· Costantino et al.
· 2015
[cited by applicant]
US 9492559B2
· Emini et al.
· 2016
[cited by applicant]
US 9517274B2
· Gu et al.
· 2016
[cited by applicant]
US 9585950B2
· Wacker et al.
· 2017
[cited by applicant]
US 9700612B2
· Kowarik et al.
· 2017
[cited by applicant]
US 9849169B2
· Nagy et al.
· 2017
[cited by applicant]
US 20030199071A1
· Langermann et al.
· 2003
[cited by applicant]
US 20060228380A1
· Hausdorff et al.
· 2006
[cited by applicant]
US 20070184071A1
· Hausdorff et al.
· 2007
[cited by applicant]
US 20070184072A1
· Hausdorff et al.
· 2007
[cited by applicant]
US 20070231340A1
· Hausdorff et al.
· 2007
[cited by applicant]
US 20070231876A1
· Biemans et al.
· 2007
[cited by applicant]
US 20070253984A1
· Kandke et al.
· 2007
[cited by applicant]
US 20120276137A1
· Freese et al.
· 2012
[cited by applicant]
US 20130122033A1
· De Santis et al.
· 2013
[cited by applicant]
US 20150216996A1
· Gu et al.
· 2015
[cited by applicant]
US 20160015797A1
· Bouzari
· 2016
[cited by applicant]
US 20160158333A1
· White et al.
· 2016
[cited by applicant]
US 20160193330A1
· Eldridge et al.
· 2016
[cited by applicant]
US 20160220666A1
· Eldridge et al.
· 2016
[cited by applicant]
US 20190275134A1
· Poolman
· 2019
[cited by applicant]
US 20190275135A1
· Poolman
· 2019
[cited by applicant]
US 20200002727A1
· Feary et al.
· 2020
[cited by applicant]
US 20210268095A1
· Donald et al.
· 2021
[cited by applicant]
US 20230000966A1
· Anderson et al.
· 2023
[cited by applicant]
CA 2004810
· 1990
[cited by applicant]
EP 0372501A2
· 1989
[cited by applicant]
EP 0413378B1
· 1991
[cited by applicant]
EP 0378881B1
· 1993
[cited by applicant]
EP 0427347B1
· 1995
[cited by applicant]
EP 0471177B1
· 1995
[cited by applicant]
EP 0689454B1
· 1997
[cited by applicant]
EP 0594610B1
· 1998
[cited by applicant]
EP 0735898B1
· 1999
[cited by applicant]
EP 0761231B1
· 2000
[cited by applicant]
GB 2220211A
· 1990
[cited by applicant]
WO 9003184A1
· 1990
[cited by applicant]
WO 9101146A1
· 1991
[cited by applicant]
WO 93003765A1
· 1993
[cited by applicant]
WO 9317712A2
· 1993
[cited by applicant]
WO 9403208A1
· 1994
[cited by applicant]
WO 9520657A1
· 1995
[cited by applicant]
WO 9611711A1
· 1996
[cited by applicant]
WO 9701640A2
· 1997
[cited by applicant]
WO 9836772A1
· 1998
[cited by applicant]
WO 9857659A1
· 1998
[cited by applicant]
WO 9858668A2
· 1998
[cited by applicant]
WO 9911241A1
· 1999
[cited by applicant]
WO 9944636A2
· 1999
[cited by applicant]
WO 9952549A1
· 1999
[cited by applicant]
WO 00004922A1
· 2000
[cited by applicant]
WO 0007621A2
· 2000
[cited by applicant]
WO 0023105A2
· 2000
[cited by applicant]
WO 0037105A2
· 2000
[cited by applicant]
WO 0039299A2
· 2000
[cited by applicant]
WO 0041720A1
· 2000
[cited by applicant]
WO 0048630A1
· 2000
[cited by applicant]
WO 0056358A2
· 2000
[cited by applicant]
WO 0061761A2
· 2000
[cited by applicant]
WO 0062800A2
· 2000
[cited by applicant]
WO 0104148A2
· 2001
[cited by applicant]
WO 0121152A1
· 2001
[cited by applicant]
WO 0121207A2
· 2001
[cited by applicant]
WO 0172337A1
· 2001
[cited by applicant]
WO 0198334A2
· 2001
[cited by applicant]
WO 0204496A2
· 2002
[cited by applicant]
WO 02053181A1
· 2002
[cited by applicant]
WO 02091998A2
· 2002
[cited by applicant]
WO 03054007A2
· 2003
[cited by applicant]
WO 2004081515A2
· 2004
[cited by applicant]
WO 2004083251A2
· 2004
[cited by applicant]
WO 2006032499A1
· 2006
[cited by applicant]
WO 2006110381A1
· 2006
[cited by applicant]
WO 2006134423A2
· 2006
[cited by applicant]
WO 2007026190A2
· 2007
[cited by applicant]
WO 2008079653A1
· 2008
[cited by applicant]
WO 2008142034A2
· 2008
[cited by applicant]
WO 2008143709A2
· 2008
[cited by applicant]
WO 2009000826A1
· 2008
[cited by applicant]
WO 2010125480A1
· 2010
[cited by applicant]
WO 2013164334A1
· 2013
[cited by applicant]
WO 2013188539A2
· 2013
[cited by applicant]
WO 2014013375A1
· 2014
[cited by applicant]
WO 2014027302A1
· 2014
[cited by applicant]
WO 2014057109A1
· 2014
[cited by applicant]
WO 2014072405A1
· 2014
[cited by applicant]
WO 2015052344A1
· 2015
[cited by applicant]
WO 2015124769A1
· 2015
[cited by applicant]
WO 2016012587A1
· 2016
[cited by applicant]
WO 2016115328A1
· 2016
[cited by applicant]
WO 2016168324A1
· 2016
[cited by applicant]
WO 2016183501A1
· 2016
[cited by applicant]
WO 2017035181A1
· 2017
[cited by applicant]
WO 2017085586A1
· 2017
[cited by applicant]
WO 2019016187A1
· 2019
[cited by applicant]
WO 2019175147A1
· 2019
[cited by applicant]
WO 2020039359A2
· 2020
[cited by applicant]
WO 2021084429A1
· 2021
[cited by applicant]
WO 2021144369A1
· 2021
[cited by applicant]
WO 2021165928A2
· 2021
[cited by applicant]
WO 2022090893A2
· 2022
[cited by applicant]
Sarshar et al. Antibiotics 9: 397: pp. 1 of 16-16 of 16, 2009.
[cited by examiner]
Greenspan et al. Nature Biotechnology 17: 936-937, 1999.
[cited by examiner]
Lazar et al. Mol. Cellular Biol. 8: 1247-1252, 1988.
[cited by examiner]
Saha et al. J. Gen. Virol. 93: 1548-1555, 2012.
[cited by examiner]
Hannan et al, “Early Severe Inflammatory Responses to Uropathogenic
[cited by applicant]
Hannan T., and Hunstad Da, “A Murine Model for
[cited by applicant]
Haraoka M., et al. “Neutrophil recruitment and resistance to urinary tract infection”, J Infect Dis 180:1220-1229 (1999).
[cited by applicant]
Hefzy, E. and Hassuna, N., “Fluoroquinolone-Resistant Sequence Type 131 Subgroups O25b and O16 Among Extraintestinal
[cited by applicant]
Heinrichs, D., et al., “The Assembly System for the Lipopolysaccharide R2 Core-Type of
[cited by applicant]
Hong, Y. and Reeves P., “Model for the Controlled Synthesis of O-Antigen Repeat Units Involving the Waal Ligase” mSphere 1 E00074-15 (2016).
[cited by applicant]
Hull et al, “Construction and Expression of Recombinant Plasmids Encoding Type 1 or D-Mannose-Resistant Pili from a Urinary Tract Infection
[cited by applicant]
Huttner, A., et al., “Safety, Immunogenicity, and Preliminary Clinical Efficacy of a Vaccine Against Extraintestinal Pathogenic
[cited by applicant]
Huttner, A., et al., “The Development and Early Clinical Testing of the ExPEC4V Conjugate Vaccine Against Uropathogenic
[cited by applicant]
Iebba et al., “Microevolution in fimH Gene of Mucosa-Associated
[cited by applicant]
Iguchi, A., et al., “A Complete View of the Genetic Diversity of the
[cited by applicant]
Inoue, M., et al., “Safety, Tolerability and Immunogenicity of the ExPEC4V (JNJ-63871860) Vaccine for Prevention of Invasive Extraintestinal Pathogenic
[cited by applicant]
Iredell et al, “Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications”, BMJ 352:h6420 (2016).
[cited by applicant]
Jiang, L., et al., “Structure and Gene Cluster of the O-antigen of
[cited by applicant]
Joensen et al, “Rapid and Easy In Silico Serotyping of
[cited by applicant]
Johnson S., et al., “Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for
[cited by applicant]
Jolley et al, “Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications”, Wellcome Open Research 3:124 (2018).
[cited by applicant]
Jonsson, K., et al., “Structural Determination of the O-antigenic Polysaccharide from
[cited by applicant]
Kalynych, S., et al., “Structure-Guided Investigation of Lipopolysaccharide O-Antigen Chain Length Regulators Reveals Regions Critical for Modal Length Control”, J Bacteriol. 193(15): 3710-3721 (2011).
[cited by applicant]
Kalynych, S., et al., “Progress in Understanding the Assembly Process of Bacterial O-antigen”, FEMS Microbiol Rev., 38(5):1048-1065 (2014).
[cited by applicant]
Ktnik-Prastowska et al., “Glycosylation of uroplakins. Implications for bladder physiopathology”, Glycoconjugate Journal 31:623-636 (2014).
[cited by applicant]
Khatun et al, “Immunology of carbohydrate-based vaccines”, Advanced Drug Delivery Reviews 165-166:117-126 (2020).
[cited by applicant]
Kido et al, “A Single Amino Acid Substitution in a Mannosyltransferase, WbdA, Converts the
[cited by applicant]
King et al, “Lipopolysaccharide O antigen size distribution is determined by a chain extension complex of variable stoichiometry in
[cited by applicant]
Kisiela et al, “Conformational inactivation induces immunogenicity of the receptor-binding pocket of a bacterial adhesin”, PNAS 110(47):19089-19094 (2013).
[cited by applicant]
Kisiela et al, “Conformational inactivation induces immunogenicity of the receptor-binding pocket of a bacterial adhesin—Supporting Information”, 10.1073/pnas.1314395110 (2013).
[cited by applicant]
Kisiela et al, “Inhibition and Reversal of Microbial Attachment by an Antibody with Parasteric Activity against the FimH Adhesin of Uropathogenic
[cited by applicant]
Knirel, “Structure of O-Antigens”, Bacterial Lipopolysaccharides, Y.A. Knirel and M.A. Valvano (eds.), Springer-Verlag/Wien 2011, Chapter 3, pp. 41-115.
[cited by applicant]
Konadu, E., et al., Preparation, Characterization, and Immunological Properties in Mice of
[cited by applicant]
Kuo et al, “Characterization of a Recombinant Pneumolysin and Its Use as a Protein Carrier for Pneumococcal Type 18C Conjugate Vaccines”, Infection and Immunity 63(7):2706-2713 (1995).
[cited by applicant]
Lane, M., et al., “Expression of flagella is coincident with uropathogenic
[cited by applicant]
Langermann et al, “Prevention of Mucosal
[cited by applicant]
Larzabal, M., et al, “Human and Veterinary Vaccines against Pathogenic
[cited by applicant]
Lerouge and Vanderleyden, “O-antigen structural variation: mechanisms and possible roles in animal/plant-microbe interactions”, FEMS Microbiology Reviews 26(1):17-47 (2001).
[cited by applicant]
Le Trong et al, “Donor strand exchange and conformational changes during
[cited by applicant]
Letrong, I., et al., “Structural Basis for Mechanical Force Regulation of the Adhesin FimH via Finger Trap-like b Sheet Twisting”, Cell, 141:645-655 (2010).
[cited by applicant]
Liu et al, “Identification of FimH derivatives as adjuvant vaccinated with Pac that enhance protection against
[cited by applicant]
Ma, Z., et al, “Glycoconjugate Vaccine Containing
[cited by applicant]
Magala et al, “RMSD analysis of structures of the bacterial protein FimH identifies five conformations of its lectin domain”, Proteins 88(4):593-603 (2019).
[cited by applicant]
Marder et al, “Multistate Outbreak of
[cited by applicant]
Mather, “Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines”, Biology of Reproduction 23:243-252 (1980).
[cited by applicant]
Mather et al, “Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium”, Annals N.Y. Acad. Sci. 383:44-68 (1982).
[cited by applicant]
Meiland, R., et al., “Fimch antiserum inhibits the adherence of
[cited by applicant]
Mellata, M., et al, “Novel vaccine antigen combinations elicit protective immune responses against
[cited by applicant]
Meloni, E., et al., “Simplified low-cost production of O-antigen from
[cited by applicant]
Micoli, F., et al., “A Scalable Method for O-antigen Purification Applied to Various
[cited by applicant]
Milstein et al, “Hybrid hybridomas and their use in immunohistochemistry”, Nature 305(5934):537-540 (1983).
[cited by applicant]
Mobley H. and Alteri C., “Development of a Vaccine against
[cited by applicant]
Morales-Barroso, I., et al., “Bacteraemia due to non-ESBL-producing
[cited by applicant]
Moriel, D., et al., “Identification of Protective and Broadly Conserved Vaccine Antigens from the Genome of Extraintestinal Pathogenic
[cited by applicant]
Motley, M. & Fries, B., “A New Take on an Old Remedy: Generating Antibodies against Multidrug-Resistant Gram-Negative Bacteria in a Postantibiotic World”, mSphere, 2(5) e00397-17 (2017).
[cited by applicant]
Mulford, C. and Osborn M., “An intermediate step in translocation of lipopolysaccharide to the outer membrane of
[cited by applicant]
Muller-Leonnies, S., et al., “Neutralizing and Cross-Reactive Antibodies Against Enterobacterial Lipopolysaccharide”, Int J Med Microbiol., 297(5):321-40 (2007).
[cited by applicant]
Munera et al, “Recognition of the N-terminal lectin domain of FimH adhesin by the usher FimD is required for type 1 bilus biogenesis”, Molecular Microbiology 64(2):333-346 (2007).
[cited by applicant]
Munera et al, “Specific residues in the N-terminal domain of FimH stimulate type 1 fimbriae assembly in
[cited by applicant]
Murray, G., et al., “Regulation of
[cited by applicant]
Naumenko, O., “Structure and Gene Cluster of the O-antigen of
[cited by applicant]
Naumenko, O., et al., “Structural Studies on the O-polysaccharide of
[cited by applicant]
Needleman et al, “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins”, J. Mol. Biol. 48(3):443-453 (1970).
[cited by applicant]
Nicolas-Chanoine et al, “
[cited by applicant]
O'Brien, V., et al, “Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections”, Microbiol Spectrum 4(1): 1-42 (2016).
[cited by applicant]
Osawa, K., et al., “Modulation of O-antigen chain length by the wzz gene in
[cited by applicant]
PCT International Search Report and Written Opinion for International Application No. PCT/IB2019/057025 issued on Feb. 17, 2020.
[cited by applicant]
PCT International Search Report and Written Opinion for International Application No. PCT/IB2021/051457 issued on Aug. 16, 2021.
[cited by applicant]
PCT International Search Report and Written Opinion for International Application No. PCT/IB2020/060081 issued on Dec. 21, 2020.
[cited by applicant]
PCT International Search Report and Written Opinion for International Application No. PCT/IB2021/062022 mailed on Jun. 3, 2022.
[cited by applicant]
Pearson et al, “Improved tools for biological sequence comparison”, PNAS 85:2444-2448 (1988).
[cited by applicant]
Perepelov, A., et al., “Structure and Gene Cluster of the O-antigen of
[cited by applicant]
Perepelov, A., et al., “Structure and Gene Cluster of the O-antigen of
[cited by applicant]
Perepelov, A., et al., “Structure and Gene Cluster of the O-antigen of
[cited by applicant]
Phalipon, A., et al., “A Synthetic Carbohydrate-Protein Conjugate Vaccine Candidate Against Shigella Flexneri 2a Infection”, J Immunol., 182(4):2241-7 (2009).
[cited by applicant]
Phan, M., et al., “The Serum Resistome of a Globally Disseminated Multidrug Resistant Uropathogenic
[cited by applicant]
Podschun et al, “
[cited by applicant]
Poolman et al, “Extraintestinal Pathogenic
[cited by applicant]
Rabbani, S., et al, “Conformational switch of the bacterial adhesin FimH in the absence of the regulatory domain: Engineering a minimalistic allosteric system”, J. Biol. Chem., 293(5): 1835-1849 (2018).
[cited by applicant]
Reyes E., et al., Mechanisms of O-Antigen Structural Variation of Bacterial Lipopolysaccharide (LPS). Chapter 3, The Complex World of Polysaccharides. IntechOpen (2012).
[cited by applicant]
Rodriguez et al, “Allosteric Coupling in the Bacterial Adhesive Protein FimH”, The Journal of Biological Chemistry 288(33):24128-24139 (2013).
[cited by applicant]
Rogers et al, “
[cited by applicant]
Ronald, L., et al., “Adaptive mutations in the signal peptide of the type 1 fimbrial adhesin of uropathogenic
[cited by applicant]
Ruiz-Argüello et al., “Thermostability of the human respiratory syncytial virus fusion protein before and after activation: implications for the membrane-fusion mechanism”, Journal of General Virology 85(12):3677-3687 (…
[cited by applicant]
Russo et al., “Medical and economic impact of extraintestinal infections due to
[cited by applicant]
Sarkar et al, “Role of Capsule and O Antigen in the Virulence of Uropathogenic
[cited by applicant]
Sato, T., et al. , “Tigecycline Nonsusceptibility Occurs Exclusively in Fluoroquinolone-Resistant
[cited by applicant]
Sauer, M., et al, “Catch-bond mechanism of the bacterial adhesin FimH”, Nat. Commun. 7:10738 doi: 10.1038/ncomms 10738 (2016).
[cited by applicant]
Schembri et al, “Expression and purification of the mannose recognition domain of the FimH adhesin”, FEMS Microbiology Letters 188:147-151 (2000).
[cited by applicant]
Schrag et al, “Epidemiology of Invasive Early-Onset Neonatal Sepsis, 2005 to 2014”, Pediatrics 138(6):e20162013 (2016).
[cited by applicant]
Schwartz et al, “Population Dynamics and Niche Distribution of Uropathogenic
[cited by applicant]
Schwartz et al, “Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation”, PNAS 110(39):15530-15537 (2013).
[cited by applicant]
Shang, W., et al., “Chemical Synthesis of the Outer Core Oligosaccharide of
[cited by applicant]
Sheikh, A., et al., “Highly conserved type 1 pili promote enterotoxigenic
[cited by applicant]
Sihra, N., et al., “Nonantibiotic prevention and management of recurrent urinary tract infection”, Nat Rev Urol 15: 750-776 (2018).
[cited by applicant]
Sjölander et al., “ISCOMs: an adjuvant with multiple functions”, Journal of Leukocyte Biology 64:713-723 (1998).
[cited by applicant]
Smith, SN, “Dissemination and systemic colonization of uropathogenic
[cited by applicant]
Starks et al, “Optimization and qualification of an assay that demonstrates that a FimH vaccine induces functional antibody responses in women with histories of urinary tract infections”, Human Vaccines & Immunotherapeu…
[cited by applicant]
Stenutz, R., et al., The Structures of
[cited by applicant]
Stoll et al, “Early Onset Neonatal Sepsis: The Burden of Group B Streptococcal and
[cited by applicant]
Summers et al, A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures; Texas Agricultural Experiment Station Bulletin No. 1555 (1987).
[cited by applicant]
Szijarto, V., et al., “Diagnostic Potential of Monoclonal Antibodies Specific to the Unique O-Antigen of Multidrug-Resistant Epidemic
[cited by applicant]
Szijarto, V., et al., “Bactericidal monoclonal antibodies specific to the lipopolysaccharide O antigen from multidrug-resistant
[cited by applicant]
Taylor, C., et al., Mutations in the waaR Gene of
[cited by applicant]
Tchesnokova, V., et al, “Type 1 Fimbrial Adhesin FimH Elicits an Immune Response That Enhances Cell Adhesion of
[cited by applicant]
Thelwall et al, “Annual Epidemiological Commentary: Mandatory MRSA, MSSSA and
[cited by applicant]
Thumbikat et al, “Bacteria-Induced Uroplakin Signaling Mediates Bladder Response to Infection”, PLoS Pathogens 5(5):e1000415 (2009).
[cited by applicant]
Tocilj, A., et al., “Bacterial polysaccharide co-polymerases share a common framework for control of polymer length” Nat Struct Mol Biol 15:130-138 (2008).
[cited by applicant]
Uchida et al., “Mutation in the Structural Gene for Diphtheria Toxin Carried by Temperate Phage Beta”, Nature New Biology 233:8-11 (1971).
[cited by applicant]
Uchida et al., “Diphtheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphtheria toxin”, J Biol Chem 248(11):3838-3844 (1973).
[cited by applicant]
Urlaub et al., “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity”, Proc. Natl. Acad. Sci. USA 77(7):4216-4220 (1980).
[cited by applicant]
Van den Dobbelsteen et al., “Immunogenicity and safety of a tetravalent
[cited by applicant]
Vetsch et al., “Chaperone-independent Folding of Type 1 Pilus Domains”, J. Mol. Biol. 322(4):827-840 (2002).
[cited by applicant]
Vimont, S., et al., “The CTX-M-15-producing
[cited by applicant]
Vinogradov et al, “Structures of Lipopolysaccharides from Klebsiella pneumoniae: Elucidation of the Structure of the Linkage Region Between Core and Polysaccharide O Chain and Identification of the Residues at the Non-R…
[cited by applicant]
Weissman et al, “Clonal analysis reveals high rate of structural mutations in fimbrial adhesins of extraintestinal pathogenic
[cited by applicant]
Whitfield, C., et al, Molecular Insights Into the Assembly and Diversity of the Outer Core Oligosaccharide in Lipopolysaccharides from
[cited by applicant]
Wick et al, “Kaptive Web: User-Friendly Capsule and Lipopolysaccharide Serotype Prediction for Klebsiella Genomes”, Journal of Clinical Microbiology 56(6):e00197-18 (2018).
[cited by applicant]
Wirth et al, “Sex and virulence in
[cited by applicant]
Wizemann, T., et al., “Adhesins as Targets for Vaccine Development”, Emerg Infect Dis, 5(3): 395-403 (1999).
[cited by applicant]
Wolf, M., Occurrence, Distribution, and Associations of O and H serogroups, Colonization Factor Antigens, and Toxins of Enterotoxigenic
[cited by applicant]
Woodward, R., et al., “In vitro bacterial polysaccharide biosynthesis: defining the functions of Wzy and Wzz.” Nat Chem Biol., 6(6):418-23 (2010).
[cited by applicant]
Yinnon et al., “Klebsiella bacteraemia: community versus nosocomial infection”, Q J Med 89(12):933-941 (1996).
[cited by applicant]
Zhou, G., et al., “Uroplakin la is the urothelial receptor for uropathogenic
[cited by applicant]
Zowawi et al, “The emerging threat of multidrug-resistant Gram-negative bacteria in urology”, Nature Reviews Urology 12:570-584 (2015).
[cited by applicant]
Abbanat, D., et al., “Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated
[cited by applicant]
Al-Hasan et al, “Antimicrobial resistance trends of
[cited by applicant]
Alonso-Caballero, A., et al., “Mechanical architecture and folding of
[cited by applicant]
Amor, K., et al., “Distribution of core oligosaccharide types in lipopolysaccharides from
[cited by applicant]
Anderson et al, “Bloodstream Infections in Community Hospitals in the 21st Century: A Multicenter Cohort Study”, PLoS ONE 9(3): e91713 (2014).
[cited by applicant]
Appelmelk, B., et al., “Frequencies of lipopolysaccharide core types in
[cited by applicant]
Aprikian, P., et al., “The Bacterial Fimbrial Tip Acts as a Mechanical Force Sensor”, PLoS Biol 9(5):e1000617 (2011).
[cited by applicant]
Baliban, S., et al., “Development of a glycoconjugate vaccine to prevent invasive
[cited by applicant]
Bameri, Z., et al., “High Yield Expression and Modified Purification of Novel Recombinant Truncated Protein FimH. MrpH against Urinary Tract Infections by
[cited by applicant]
Baraldo et al, “N19 Polyepitope as a Carrier for Enhanced Immunogenicity and Protective Efficacy of Meningococcal Conjugate Vaccines”, Infection and Immunity 72(8):4884-4887 (2004).
[cited by applicant]
Barnhart et al, “PapD-like chaperones provide the missing information for folding of pilin proteins”, PNAS 97 (14):7709-7714 (2000).
[cited by applicant]
Barnhart et al, “Chaperone-Subunit-Usher Interactions Required for Donor Strand Exchange during Bacterial Pilus Assembly”, Journal of Bacteriology 185(9):2723-2730 (2003).
[cited by applicant]
Bauchart et al, “Pathogenomic comparison of human extraintestinal and avian pathogenic
[cited by applicant]
Behrens, R., et al., “Efficacy and safety of a patch vaccine containing heat-labile toxin from
[cited by applicant]
Bennett-Guerrero, E., et al., “Preparation and Preclinical Evaluation of a Novel Liposomal Complete-Core Lipopolysaccharide Vaccine”, Infect Immun. 68(11):6202-6208 (2000).
[cited by applicant]
Bouckaert et al, “Receptor binding studies disclose a novel class of high-affinity inhibitors of the
[cited by applicant]
Bourgeois, A., et al., “Status of vaccine research and development for enterotoxigenic
[cited by applicant]
Brown et al, “Structure of the streptococcal cell wall C5a peptidase”, Proc. Natl. Acad. Sci. USA 102 (51):18391-18396 (2005).
[cited by applicant]
Brumbaugh, A., et al., Preventing urinary tract infection: progress toward an effective
[cited by applicant]
Buckles et al, “Role of the K2 Capsule in
[cited by applicant]
Burns et al, “Loss of Resistance to Ingestion and Phagocytic Killing by O- and K- Mutants of a Uropathogenic
[cited by applicant]
Céspedes et al, “Genetic Diversity and Virulence Determinants of
[cited by applicant]
Chakraborty, S., Human Experimental Challenge With Enterotoxigenic
[cited by applicant]
Chen, S., et al., “Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding”, PNAS 106(52): 22439-22444 (2009).
[cited by applicant]
Chen et al, “Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding”, Trends in Microbiology 22(12):686-696 (2014).
[cited by applicant]
Chmielewski, M., et al., “FimH-based display of functional eukaryotic proteins on bacteria surfaces”, Scientific Reports 9:8410 s41598-019-44883 (2019).
[cited by applicant]
Clarke et al, “Coordination of Polymerization, Chain Termination, and Export in Assembly of the
[cited by applicant]
Clermont, O., et al., Determination of
[cited by applicant]
Cryz, S.J., “Synthesis and Characterization of a Polyvalent
[cited by applicant]
Cusumano et al, “Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors”, Science Translational Medicine 3(109):109ra115 (2011).
[cited by applicant]
Debroy, C., et al., Comparison of O-Antigen Gene Clusters of All O-Serogroups of
[cited by applicant]
Diancourt et al, “Multilocus Sequence Typing of Klebsiella pneumoniae Nosocomial Isolates”, Journal of Clinical Microbiology 43(8):4178-4182 (2005).
[cited by applicant]
Douglas et al, “Exotoxin A of Pseudomonas aeruginosa: Substitution of Glutamic Acid 553 with Aspartic Acid Drastically Reduces Toxicity and Enzymatic Activity”, Journal of Bacteriology 169(11):4967-4971).
[cited by applicant]
Dreux et al, “Point Mutations in FimH Adhesin of Crohn's Disease-Associated Adherent-Invasive
[cited by applicant]
Durant, L., et al., “Identification of candidates for a subunit vaccine against extraintestinal pathogenic
[cited by applicant]
Falugi et al, “Rationally designed strings of promiscuous CD4+ T cell epitopes provide help to Haemophilus Influenzae type b oligosaccharide: a model for new conjugate vaccines”, Eur. J. Immunol. 31:3816-3824 (2001).
[cited by applicant]
Feenstra et al, “Adhesion of
[cited by applicant]
Feldman, M., et al., “Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in
[cited by applicant]
Follador et al, “The diversity of Klebsiella pneumoniae surface polysaccharides”, Microbial Genomics 2:e000073 (2016).
[cited by applicant]
Forde, B., et al., “The complete genome sequence of
[cited by applicant]
Franco, A., et al., “A Wzz (Cld) Protein Determines the Chain Length of K Lipoploysaccharide in
[cited by applicant]
Ghosh et al, “Incidence of multidrug resistance, pathogenicity island markers, and pathoadaptive FimH mutations in uropathogenic
[cited by applicant]
Giedraitiene, A., et al., “Prevalence of O25b-ST131 clone among
[cited by applicant]
Graham et al, “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5”, J. Gen. Virol. 36(1):59-74 (1977).
[cited by applicant]
Green, S., et al., “Murine model of chemotherapy-induced extraintestinal pathogenic
[cited by applicant]
Greenfield et al, “Biosynthesis of the Polymannose Lipopolysaccharide O-antigens from
[cited by applicant]
Guachalla et al, “Discovery of monoclonal antibodies cross-reactive to novel subserotypes of K. pneumoniae O3”, Scientific Reports 7:6635 (2017).
[cited by applicant]
Jagan E. and Mobley H., “Uropathogenic
[cited by applicant]
Han D., et al., “Regulation of the O-antigen polysaccharide chain length by Wzz—a review”, Acta Microbiologica Sinica 54(9):971-976 (2014).
[cited by applicant]
Franco et al, “The Wzz (Cld) Protein in
[cited by applicant]
Frenck, R., et al., Long-term Immunogenicity and Safety of ExPEC4V Vaccine Against Extraintestinal Pathogenic
[cited by applicant]
Kurupati et al, “Identification of vaccine candidate antigens of an ESBL producing Klebsiella pneumoniae clinical strain by immunoproteome analysis”, Proteomics 6:836-844 (2006).
[cited by applicant]
Yakovenko et al., “Inactive conformation enhances binding function in physiological conditions”, PNAS 112 (32):9884-9889 (2015).
[cited by applicant]
Singaravelu, M., et al., “Molecular dynamics simulations of lectin domain of FimH and immunoinformatics for the design of potential vaccine candidates”, Computational Biology and Chemistry, 2014, 52:18-24.
[cited by applicant]